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Abstract
Introduction: The presence of anti-Ro52 antibodies has been reported in a wide variety of autoimmune diseases, 
particularly in myositis, scleroderma and autoimmune liver diseases. Clinical significance of anti-Ro52 antibodies 
remains controversial. Studies are lacking in clarifying the association of anti-Ro52 with pulmonary involvement in 
scleroderma. 
Objectives: To determine if anti-Ro52 antibodies are associated with pulmonary involvement (interstitial, indirect 
pulmonary hypertension, or both) in scleroderma. 
Methods: Single center, retrospective study based on immunoblotting panel analysis and patients clinical records.
Pulmonary manifestations were sub-grouped in: 1) interstitial (alveolitis and/or fibrosis), 2) pulmonary artery systolic 
pressure (PASP) ≥40 mmHg plus interstitial pulmonary disease, and 3) isolated PASP≥40 mmHg (purely vascular).
Results: Our scleroderma cohort included 200 patients, of which 137 had immunoblotting panels with anti-Ro52 
reactivity analysis. The search was conducted between January 2010 and July 2011.
The frequency of pulmonary manifestations in patients with positive anti-Ro52 antibodies was 67.7% (n=31), and 
60% (n=24) in the negative anti-Ro52 group, showing no significant differences between groups (p=0.621).
Still no significant differences were found when pulmonary manifestations were evaluated according to the 
subgroups (p=0.525).
Sensitivity, specificity, positive and negative predictive values of anti-Ro52 reactivity for determining pulmonary 
involvement in scleroderma were low.
Conclusion: No association was found between positive anti-Ro52 antibodies and pulmonary involvement in 
scleroderma.
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Introduction
Antibodies to SSA antigen (Ro52/Ro60), were historically described 
as a marker for Sjögren syndrome and systemic lupus erythematosus 
[1]. However, recent publications [2,3] have demonstrated that 
Ro52 and Ro60 (SSA) antigens consisted of two different proteins 
representing two distinct autoantibodies systems and have different 
clinical associations. In clinical practice is desirable to detect these 
autoantibodies separately [4].
The Ro52 gene has been mapped to the end of the short arm of 
human chromosome 11 [5] and Ro52 antigen has recently been 
identified as a 52 kDa protein, belonging to the tripartite motif (TRIM) 
protein family [6]. So, anti-Ro52 antibodies can also be named as anti-
TRIM21 antibodies. 
Clinical significance of anti-Ro52/TRIM21 antibodies remains 
controversial [7,8]. 
The presence of anti-Ro52 antibodies has been reported in a wide 
variety of autoimmune diseases, particularly in myositis, scleroderma and 
autoimmune liver diseases [9,10], and have been associated with non-
autoimmune diseases such as viral infections or neoplastic diseases [11].
Some studies found association between anti-Ro52 reactivity and 
scleroderma [12]. Others described association between anti-Ro52 
reactivity and interstitial lung disease [7]. No association between anti-
Ro52 antibodies, scleroderma and interstitial lung disease altogether 
was found in the reviewed literature.
The scarce information about this issue has led to the development 
of this study.
Objectives
To determine if anti-Ro52 antibodies are associated with pulmonary 
manifestations in scleroderma. 
Methods
Studied population
In this single center, retrospective study, the patients were selected 
on the basis of immunoblotting panels (EUROLINE®) results and 
patients clinical records.
Inclusion criteria
Patients followed in our center with scleroderma diagnosis criteria 
Volume 2 • Issue ? • 1000116
J Pulmonar Respirat Med
ISSN: 2161-105X JPRM, an open access journal
Citation: Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C (2012) Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in 
Scleroderma?. J Pulmonar Respirat Med 2:116. doi:10.4172/2161-105X.1000116
Page 2 of 3
[13], which had a pulmonary computed tomography (CT) scan and an 
echocardiogram performed.
Definitions
Pulmonary manifestations were sub-grouped in: 1) interstitial 
(alveolitis and/or fibrosis), 2) pulmonary artery systolic pressure 
(PASP) ≥40 mmHg plus interstitial pulmonary disease, and 3) isolated 
PASP≥40 mmHg (purely vascular) [14].
Interstitial pulmonary involvement was determined by 
radiologist interpretation of high-resolution CT scan (HRCT) and/or 
bronchoalveolar lavage results. 
Doppler study is the most accurate non-invasive measure of PASP 
with a sensitivity of 90% and a specificity of 75% compared with right 
heart catheterization [15]. An important point of discussion is the 
definition of the cut-off value to distinguish normal from abnormal 
PASP. Some authors consider normal an estimated PASP lower than 
30 mmHg [14]. In our center we consider a PASP ≥40 mmHg highly 
suggestive of pulmonary arterial hypertension (PAH) and a potential 
indication for right heart catheterisation. For this study purposes we 
assume that patients with PASP ≥40 mmHg are likely to have elevated 
pulmonary artery pressure.
Data analysis
Data were registered in Excel® and IBM SPSS software version 19® 
was used for statistical analysis. For proportion analysis chi-square 
or Fisher tests were used. A significance (p) < 0,05 was defined. 
Complementary information in data analysis is mentioned along the 
text and tables.
Results
Our scleroderma cohort included 200 patients, of which 137 had 
immunoblotting panels with anti-Ro52 reactivity analysis. The search 
was conducted between January 2010 and July 2011. 
Of the 137 patients with anti-Ro52 reactivity analysis, 71 (51.8%) 
had inclusion criteria: 93% (n=66) were women and 7% (n=5) were 
men, with a mean (SD) age of 56.4 (14.5) years.
Among the 71 selected sera, 43.7% (n=31) had anti-Ro52 reactivity. 
Among the 31 positive sera, 22.6% (n=7) showed isolated anti-Ro52 
antibodies and 77.4% (n=24) showed anti-Ro52 antibodies associated 
with at least another antibody. 
The gender distribution and mean age (SD) of the positive anti-
Ro52 group were similar to the initial group (96.8% women; 54.6 (13.7) 
years, respectively).
Altogether the frequency of pulmonary manifestations in the 
positive anti-Ro52 antibodies was 67.7% (n=31), and 60% (n=24) in the 
negative anti-Ro52 group. No significant differences between groups 
were found (p=0.621). 
Pulmonary manifestations were also evaluated according to the 
subgroups-1) interstitial (alveolitis and/or fibrosis), 2) PASP≥40 mmHg 
plus interstitial pulmonary disease, and 3) isolated PASP ≥40 mmHg 
(purely vascular). Still no significant differences were found (Table 1).
Calculations for sensitivity (48.7%), specificity (44.4%), positive 
(66.7%) and negative (43.2%) predictive values of anti-Ro52 reactivity 
for determining interstitial pulmonary involvement in scleroderma are 
detailed in Table 2.
Among patients with interstitial pulmonary involvement (n=41), 
39% (n=16) had positive anti-Scl70 antibodies. In the group of patients 
without interstitial pulmonary involvement (n=26), only 7.7% (n=2) 
had positive anti-Scl70 antibodies. Significant differences between 
groups were found (p=0,005).
Among patients with interstitial pulmonary involvement (n=41), 
53.7% (n=22) had positive anti-centromere antibodies. In the group 
of patients without interstitial pulmonary involvement (n=26), 76.9% 
(n=20) had positive anti-centromere antibodies. No significant 
differences between groups were found (p=0,06). All patients (n=4) 
with isolated PASP ≥40 mmHg (purely vascular) had positive anti-
centromere antibodies.
Anti-Ro52 antibodies were not associated with anti-Scl70, nor anti-
centromere antibodies (p=0,116 and p=0,646, respectively).
Discussion
Isolated anti-Ro52 antibodies were detected in various autoimmune 
diseases. Some authors describe an association between anti-Ro52 
antibodies and interstitial lung disease [7]. 
Some studies report an association of anti-Ro52 antibodies 
with aggressive anti-tRNA synthetases syndrome [16,17]. However, 
there have been relatively few studies addressing the frequency of 
anti-Ro52 antibodies in scleroderma and no comprehensive reports 
assessing associations of anti-Ro-52 with the specific autoantibodies 
that are characteristic of scleroderma [12]. In addition, after extensive 
MEDLINE/PubMed review, we did not find studies reporting an 
association of anti-Ro52 with pulmonary involvement in scleroderma. 
In a large study [12] the authors analysed sera from a substantial 
cohort of scleroderma patients representing the entire spectrum 
of disease. Anti-Ro52 was found to be present at a frequency of at 
least 15% in all antibody groups tested. This frequency appeared to 
be greater than previously described [18,19]. The data presented in 
this study demonstrate that anti-Ro52 is prevalent throughout the 
scleroderma supporting the hypothesis that anti-Ro52 is a general 
serum marker with limited linkage to a myositis phenotype or other 
clinical manifestations of scleroderma.
In our study the prevalence of anti-Ro52 antibodies was even greater 
than previously described [12,18,19] reaching 43.7% of the tested sera. 
The data presented in our study demonstrate that anti-Ro52 antibodies 
lack sensitivity, specificity and predictive values for pulmonary 
involvement diagnosis in scleroderma. In addition, no independent 
association was found between anti-Ro52 reactivity and pulmonary 
disease even when pulmonary manifestations where subgrouped in 
Anti-Ro52 antibody
Pulmonary involvement Positive n (%) Negative n (%) p
Isolated Interstitial (alveolitis and/
or fibrosis)
20 (64.5%) 21 (52.5%) 0.525*
PASP ≥40 plus Interstitial 1 (3.1%) 3 (7.5%) 0.525*
Isolated PASP ≥40 (purely vascular) 4 (12.9%) 8 (20%) 0.322*
Table 1: Pulmonary involvement in relation to anti-Ro52
PASP, pulmonary artery systolic pressure (mmHg)
*Chi-square test
(CI 95%)
IPI PARo52A Ss, % Sp, % PPV, % NPV, %
n=41 n=20 48.7 (29-71) 44.4 (20-68) 66.7 (46-88) 43.2 (19-67)
Table 2: Sensitivity (Ss), specificity (Sp), positive (PPV) and negative (NPV) pre-
dictive values of anti-Ro52 reactivity in determining pulmonary involvement in 
scleroderma
IPI, interstitial pulmonary involvement; PARo52A, positive anti-Ro52 antibodies.
Volume 2 • Issue ? • 1000116
J Pulmonar Respirat Med
ISSN: 2161-105X JPRM, an open access journal
Citation: Ferreira JP, Almeida I, Marinho A, Cerveira C, Vasconcelos C (2012) Are Anti-Ro52 Antibodies Associated with Pulmonary Involvement in 
Scleroderma?. J Pulmonar Respirat Med 2:116. doi:10.4172/2161-105X.1000116
Page 3 of 3
interstitial (alveolitis and/or fibrosis), PASP≥40 mmHg plus interstitial 
pulmonary disease, and isolated PASP ≥40 mmHg (purely vascular). 
These findings are supported by previous studies [12]. 
Our study has several limitations: it is a short cross-sectional study; 
the diffusion capacity for carbon monoxide was not addressed; the 
lung CT scores were not performed; echocardiography has important 
limitations for diagnosing PASP elevation etiology [20-23]. 
In fact, our study confirmed some associations previously 
described: anti-Scl70 antibodies with interstitial pulmonary disease 
and anti-centromere antibodies with potential vascular pulmonary 
hypertension [24-26]. 
Conclusion
No association was found between positive anti-Ro52 antibodies 
and pulmonary involvement in scleroderma.
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